| Bioactivity | KVI-020 is an orally active, potent and selective blocker of the atrial potassium channel Kv1.5, with an IC50 of 480 nM. KVI-020 can inhibits hERG, with an IC50 of 15100 nM. KVI-020 is a potent antiarrhythmic agent, and can be used for atrial fibrillation (AF) research[1]. |
| Target | IC50: 480 ± 44 nM (Kv1.5), 15100 nM (hERG) |
| Name | KVI-020 |
| CAS | 1000306-34-2 |
| Formula | C20H25N3O5S |
| Molar Mass | 419.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Blass BE, et al. Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia. J Med Chem. 2009 Nov 12;52(21):65 |
KVI-020
CAS: 1000306-34-2 F: C20H25N3O5S W: 419.49
KVI-020 is an orally active, potent and selective blocker of the atrial potassium channel Kv1.5, with an IC50 of 480 nM.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.